M
M. R. Soeters
Researcher at University of Amsterdam
Publications - 2
Citations - 304
M. R. Soeters is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Quality of life & Cumulative dose. The author has an hindex of 2, co-authored 2 publications receiving 241 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' Orbitopathy
Luigi Bartalena,G. E. Krassas,Wilmar M. Wiersinga,Claudio Marcocci,Mario Salvi,Chantal Daumerie,C Bournaud,M Stahl,L. Sassi,Giovanni Veronesi,Claudio Azzolini,Kostas G. Boboridis,M. P. Mourits,M. R. Soeters,L Baldeschi,Marco Nardi,Nicola Currò,Antonella Boschi,M Bernard,G von Arx +19 more
TL;DR: A multicenter, randomized, double-blind trial to determine efficacy and safety of three doses of i.v. methylprednisolone for Graves' orbitopathy, finding that the 7.47-g dose provides short-term advantages over lower doses, but this benefit is transient and associated with slightly greater toxicity.
Journal ArticleDOI
Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy?
Luigi Bartalena,Giovanni Veronesi,G. E. Krassas,W. M. Wiersinga,Claudio Marcocci,Michele Marinò,Mario Salvi,Chantal Daumerie,C Bournaud,M Stahl,L. Sassi,Claudio Azzolini,Kostas G. Boboridis,M. P. Mourits,M. R. Soeters,L Baldeschi,Marco Nardi,Nicola Currò,Antonella Boschi,M Bernard,G von Arx,Petros Perros,George J. Kahaly +22 more
TL;DR: Patients who deteriorate at 6 weeks after iv GCs are unlikely to benefit from continuing ivGCs, and they may continue ivGC treatment, or, alternatively, possibly stop ivGCS and be switched to a second-line treatment.